CN114245745A - 靶向pik3ca突变的t细胞受体及其用途 - Google Patents

靶向pik3ca突变的t细胞受体及其用途 Download PDF

Info

Publication number
CN114245745A
CN114245745A CN202080057384.4A CN202080057384A CN114245745A CN 114245745 A CN114245745 A CN 114245745A CN 202080057384 A CN202080057384 A CN 202080057384A CN 114245745 A CN114245745 A CN 114245745A
Authority
CN
China
Prior art keywords
seq
amino acid
acid sequence
variable region
chain variable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080057384.4A
Other languages
English (en)
Chinese (zh)
Inventor
C·A·克莱巴诺夫
S·S·钱德兰
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Memorial Sloan Kettering Cancer Center
Original Assignee
Memorial Sloan Kettering Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Memorial Sloan Kettering Cancer Center filed Critical Memorial Sloan Kettering Cancer Center
Publication of CN114245745A publication Critical patent/CN114245745A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4244—Enzymes
    • A61K40/4251—Kinases, e.g. Raf or Src
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/01—Phosphotransferases with an alcohol group as acceptor (2.7.1)
    • C12Y207/01137—Phosphatidylinositol 3-kinase (2.7.1.137)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/01—Phosphotransferases with an alcohol group as acceptor (2.7.1)
    • C12Y207/01153—Phosphatidylinositol-4,5-bisphosphate 3-kinase (2.7.1.153), i.e. phosphoinositide 3-kinase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/11—Protein-serine/threonine kinases (2.7.11)
    • C12Y207/11001—Non-specific serine/threonine protein kinase (2.7.11.1), i.e. casein kinase or checkpoint kinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Hematology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
CN202080057384.4A 2019-06-20 2020-06-19 靶向pik3ca突变的t细胞受体及其用途 Pending CN114245745A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962864148P 2019-06-20 2019-06-20
US62/864,148 2019-06-20
PCT/US2020/038592 WO2020257553A1 (en) 2019-06-20 2020-06-19 T cell receptors targeting pik3ca mutations and uses thereof

Publications (1)

Publication Number Publication Date
CN114245745A true CN114245745A (zh) 2022-03-25

Family

ID=74040933

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080057384.4A Pending CN114245745A (zh) 2019-06-20 2020-06-19 靶向pik3ca突变的t细胞受体及其用途

Country Status (6)

Country Link
US (1) US12492237B2 (https=)
EP (1) EP3986450A4 (https=)
JP (2) JP7730298B2 (https=)
CN (1) CN114245745A (https=)
CA (1) CA3144054A1 (https=)
WO (1) WO2020257553A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117736310A (zh) * 2023-12-15 2024-03-22 重庆医科大学 一种hla-a1101限制性抗原表位肽、靶向表位肽tcr及其应用

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024220827A1 (en) * 2023-04-21 2024-10-24 Abata Therapeutics, Inc. Cell therapies for type 1 diabetes
WO2025034618A1 (en) * 2023-08-04 2025-02-13 Vcreate, Inc. A novel t-cell receptor and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108884143A (zh) * 2016-03-16 2018-11-23 伊玛提克斯生物技术有限公司 用于癌症免疫治疗的转染t细胞和t细胞受体
CN108884136A (zh) * 2016-03-16 2018-11-23 伊玛提克斯生物技术有限公司 用于癌症免疫治疗的转染t细胞和t细胞受体

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
EP2052088A2 (en) 2006-08-02 2009-04-29 Genizon Biosciences Genemap of the human genes associated with psoriasis
WO2008060510A2 (en) 2006-11-13 2008-05-22 Sangamo Biosciences, Inc. Zinc finger nuclease for targeting the human glucocorticoid receptor locus
WO2009146179A1 (en) 2008-04-15 2009-12-03 University Of Iowa Research Foundation Zinc finger nuclease for the cftr gene and methods of use thereof
CN102174576A (zh) 2011-01-25 2011-09-07 西北农林科技大学 一种由锌指核酸酶介导的哺乳动物内源基因定向敲除的方法和该锌指核酸酶及其表达载体
WO2013163628A2 (en) 2012-04-27 2013-10-31 Duke University Genetic correction of mutated genes
CN103668470B (zh) 2012-09-12 2015-07-29 上海斯丹赛生物技术有限公司 一种dna文库及构建转录激活子样效应因子核酸酶质粒的方法
GB2508414A (en) 2012-11-30 2014-06-04 Max Delbrueck Centrum Tumour specific T cell receptors (TCRs)
US8697359B1 (en) 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
WO2014134412A1 (en) 2013-03-01 2014-09-04 Regents Of The University Of Minnesota Talen-based gene correction
JP6712948B2 (ja) 2013-12-12 2020-06-24 ザ・ブロード・インスティテュート・インコーポレイテッド 組成物、及びヌクレオチドリピート障害におけるｃｒｉｓｐｒ−ｃａｓ系の使用方法
EP3690044B1 (en) 2014-02-11 2024-01-10 The Regents of the University of Colorado, a body corporate Crispr enabled multiplexed genome engineering
MX375379B (es) * 2014-05-29 2025-03-06 Us Health Receptores de celulas t anti - papilomavirus 16 e7 humano.
IL294183B2 (en) * 2015-05-20 2023-10-01 Dana Farber Cancer Inst Inc shared neoantigens
DE102017106305A1 (de) 2017-03-23 2018-09-27 Immatics Biotechnologies Gmbh Neue T-Zellrezeptoren und deren Verwendung in Immuntherapien gegen prame-positive Krebsarten
EP4252759B1 (en) * 2018-05-11 2025-08-06 Memorial Sloan Kettering Cancer Center T cell receptors targeting pik3ca mutations and uses thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108884143A (zh) * 2016-03-16 2018-11-23 伊玛提克斯生物技术有限公司 用于癌症免疫治疗的转染t细胞和t细胞受体
CN108884136A (zh) * 2016-03-16 2018-11-23 伊玛提克斯生物技术有限公司 用于癌症免疫治疗的转染t细胞和t细胞受体

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117736310A (zh) * 2023-12-15 2024-03-22 重庆医科大学 一种hla-a1101限制性抗原表位肽、靶向表位肽tcr及其应用
CN117736310B (zh) * 2023-12-15 2025-03-18 重庆医科大学 一种hla-a1101限制性抗原表位肽、靶向表位肽tcr及其应用

Also Published As

Publication number Publication date
US12492237B2 (en) 2025-12-09
EP3986450A1 (en) 2022-04-27
EP3986450A4 (en) 2023-06-28
JP2025061710A (ja) 2025-04-11
JP7730298B2 (ja) 2025-08-27
JP2022537553A (ja) 2022-08-26
CA3144054A1 (en) 2020-12-24
WO2020257553A1 (en) 2020-12-24
US20220110976A1 (en) 2022-04-14

Similar Documents

Publication Publication Date Title
CN109803983B (zh) 靶向nkg2dl的特异性嵌合抗原受体t细胞，其制备方法和应用
CN113454115B (zh) 靶向唾液酸化路易斯a的嵌合抗原受体及其用途
US20240091361A1 (en) T cell receptors targeting ras mutations and uses thereof
JP2025061710A (ja) Ｐｉｋ３ｃａ変異を標的にするｔ細胞レセプターおよびその使用
US20250313606A1 (en) T cell receptors targeting pik3ca mutations and uses thereof
WO2024093056A1 (zh) Kras_g12v突变抗原特异性tcr及其与cd8共表达重定向cd4 t细胞
WO2023133540A1 (en) Il-12 affinity variants
JP2026513241A (ja) Ｂｃｍａおよびｃｄ１９を標的とする二重特異性ｃａｒ－ｔ細胞
WO2022166665A1 (zh) 一种以内源性蛋白质分子替代单结构域抗体的嵌合抗原受体
HK40070453A (en) T cell receptors targeting pik3ca mutations and uses thereof
KR20240004453A (ko) 변형된 과립구 집락-자극 인자(g-csf) 및 이에 결합하는 키메라 사이토카인 수용체
WO2025124489A1 (zh) Kras_g12d突变抗原特异性tcr及其与cd8共表达重定向cd4 t细胞
JP2025501358A (ja) Ｔ細胞受容体、その製造方法、及び使用
AU2023306306A1 (en) Recombinant cytokine receptors and methods of use
WO2026021544A1 (zh) 表达辅助受体的细胞
HK40101993A (zh) Kras_g12v突变抗原特异性tcr及其与cd8共表达重定向cd4 t细胞
JP2025501358A5 (https=)
HK40086029A (zh) Kras_g12v突变抗原特异性tcr及其与cd8共表达重定向cd4 t细胞
HK40086029B (zh) Kras_g12v突变抗原特异性tcr及其与cd8共表达重定向cd4 t细胞
CN117304301A (zh) 一种结合ssx2抗原的tcr分子及其应用
CN118165098A (zh) 特异性识别egfr l858r突变抗原的tcr及其用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40070453

Country of ref document: HK